Zimmer Partners LP Acquires New Shares in Pfizer Inc. (NYSE:PFE)

Zimmer Partners LP acquired a new stake in Pfizer Inc. (NYSE:PFE) during the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 834,100 shares of the biopharmaceutical company’s stock, valued at approximately $22,129,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the business. Vanguard Group Inc. lifted its position in Pfizer by 0.4% in the 4th quarter. Vanguard Group Inc. now owns 518,535,151 shares of the biopharmaceutical company’s stock valued at $13,756,738,000 after acquiring an additional 2,285,276 shares in the last quarter. Charles Schwab Investment Management Inc. lifted its position in Pfizer by 19.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 155,459,101 shares of the biopharmaceutical company’s stock valued at $4,124,330,000 after acquiring an additional 25,315,159 shares in the last quarter. Geode Capital Management LLC lifted its position in Pfizer by 2.5% in the 4th quarter. Geode Capital Management LLC now owns 120,589,782 shares of the biopharmaceutical company’s stock valued at $3,190,131,000 after acquiring an additional 2,923,537 shares in the last quarter. Norges Bank bought a new position in shares of Pfizer during the 4th quarter valued at $2,328,986,000. Finally, Massachusetts Financial Services Co. MA lifted its holdings in shares of Pfizer by 7.5% during the 4th quarter. Massachusetts Financial Services Co. MA now owns 76,502,238 shares of the biopharmaceutical company’s stock valued at $2,029,604,000 after buying an additional 5,350,381 shares during the period. 68.36% of the stock is owned by institutional investors.

Pfizer Price Performance

Shares of Pfizer stock opened at $23.01 on Tuesday. Pfizer Inc. has a one year low of $20.92 and a one year high of $31.54. The stock’s fifty day moving average is $23.60 and its 200 day moving average is $25.28. The stock has a market cap of $130.82 billion, a P/E ratio of 16.32, a P/E/G ratio of 0.64 and a beta of 0.58. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.67 by $0.25. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The business had revenue of $13.72 billion during the quarter, compared to analyst estimates of $14.43 billion. During the same quarter in the prior year, the business posted $0.82 EPS. Pfizer’s revenue for the quarter was down 7.8% compared to the same quarter last year. Sell-side analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 9th will be paid a $0.43 dividend. The ex-dividend date of this dividend is Friday, May 9th. This represents a $1.72 dividend on an annualized basis and a yield of 7.48%. Pfizer’s payout ratio is presently 124.64%.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on PFE shares. UBS Group increased their price target on Pfizer from $24.00 to $25.00 and gave the company a “neutral” rating in a report on Wednesday, April 30th. Hsbc Global Res raised Pfizer to a “strong-buy” rating in a report on Monday, March 10th. Guggenheim reissued a “buy” rating on shares of Pfizer in a report on Tuesday, March 18th. The Goldman Sachs Group reissued a “neutral” rating and set a $25.00 price target (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. Finally, Cantor Fitzgerald began coverage on Pfizer in a report on Tuesday, April 22nd. They set a “neutral” rating and a $24.00 price target on the stock. One investment analyst has rated the stock with a sell rating, eight have assigned a hold rating, four have assigned a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, Pfizer has a consensus rating of “Moderate Buy” and a consensus price target of $29.17.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.